![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products.
Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area: Oncology Product Name: Promitil
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: LipoMedix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2021
Details:
Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy.
Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area: Oncology Product Name: Promitil
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: LipoMedix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2021
Details:
Agreement provides Lupin the exclusive rights to market and distribute 2 complex injectable assets in advanced stages of development in the US and its territories.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 05, 2020